Data from the SECURE-IBD [49] and COVID-19 Global Rheumatology Alliance [50] registries demonstrated that anti-TNF therapies in patients with inflammatory bowel disease and rheumatic disease infected with COVID-19 were associated with lower hospital admission, ventilator use, and death. This evidence concerns the gene TNF and COVID-19.